AbCellera Biologics Inc

At AbCellera, we are revolutionizing the speed and efficacy of drug discovery through our groundbreaking, full-stack, AI-powered antibody discovery platform. Our technology is engineered to search, decode, and analyze natural immune systems with unprecedented depth and precision, empowering the development of novel antibody-based medicines for a wide range of diseases. By integrating advanced technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science, we have created a centralized operating system that breaks through the conventional barriers of drug development. This allows us to tackle the most challenging therapeutic problems, including those involving difficult-to-drug target classes like G protein-coupled receptors (GPCRs) and ion channels, which have historically been intractable for traditional discovery methods. Our platform's ability to screen millions of single B cells enables us to access the full diversity of natural immune responses, leading to the rapid isolation of large panels of high-quality lead candidates.

Our innovation-centric approach was born from the idea that a deep, long-term investment in technology could fundamentally change how medicines are created. Instead of focusing on a single drug, we built an engine capable of creating many. This was powerfully demonstrated by our rapid response to the COVID-19 pandemic, where our platform delivered a therapeutic antibody to the clinic in record time. Building on this success, we are continuing to expand our capabilities. We have made strategic acquisitions to enhance our protein engineering and humanized mouse technologies, and we are investing heavily in our infrastructure, including the construction of a state-of-the-art GMP manufacturing facility in Vancouver. This vertical integration from target to clinical manufacturing allows us to control the entire value chain, ensuring quality and speed. While we continue to forge partnerships with leading pharmaceutical and biotech companies, we are increasingly focusing on advancing our own internal pipeline of therapeutics in areas such as oncology, inflammation, and metabolic conditions, using our technological advantage to bring better medicines to patients, faster.